Michael Sanders, MD
Gastroenterology · Mobile, ALNPI 1275554636
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (48.9%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. AbbVie accounts for 71.7% of it on its own, with 34 other manufacturers making up the rest. Reporting peaked in 2019 at $17,494 and has fallen 95.1% since, to $861 in 2025. Among gastroenterology clinicians in AL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 561 payments — averaging $44.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$18K
- Johnson & Johnson$1K
- Ironwood Pharmaceuticals, Inc$851
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$820
- Takeda Pharmaceuticals U.S.A., Inc.$715
- Covidien LP$516
- plus $3K from 29 others
What the payments were for
- Speaking & faculty fees$12,20049%
- Travel & lodging$2,98912%
- Food & beverage$9,74339%
- Education$50%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 171 | $17,870 |
| Johnson & Johnson | 73 | $1,021 |
| Ironwood Pharmaceuticals, Inc | 44 | $851 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 70 | $820 |
| Takeda Pharmaceuticals U.S.A., Inc. | 44 | $715 |
| Covidien LP | 6 | $516 |
| Bristol Myers Squibb | 27 | $403 |
| Pfizer | 20 | $332 |
| Cook Medical LLC | 5 | $225 |
| Ardelyx, Inc. | 11 | $211 |
| Sanofi | 6 | $181 |
| Daiichi Sankyo Inc. | 11 | $177 |
| Ambu Inc. | 2 | $154 |
| Nestle Healthcare Nutrition Inc. | 6 | $140 |
| Intercept Pharmaceuticals, Inc. | 9 | $139 |
| Boston Scientific | 3 | $128 |
| Shionogi Inc | 6 | $110 |
| Endogastric Solutions, Inc | 1 | $99 |
| Braintree Laboratories, Inc. | 6 | $98 |
| Gilead | 4 | $96 |
| Conmed Corporation | 4 | $94 |
| Phathom Pharmaceuticals, Inc. | 7 | $86 |
| Madrigal Pharmaceuticals | 2 | $77 |
| Regeneron Healthcare Solutions, Inc. | 4 | $75 |
| Lilly USA, LLC | 4 | $68 |
| Medtronic | 3 | $60 |
| Merck | 2 | $35 |
| Amgen | 2 | $34 |
| Ferring Pharmaceuticals Inc. | 2 | $28 |
| QOL Medical, LLC | 1 | $19 |
| Exact Sciences | 1 | $17 |
| Endo Pharmaceuticals Inc. | 1 | $16 |
| Fujifilm Healthcare Americas Corporation | 1 | $15 |
| Redhill Biopharma Inc. | 1 | $14 |
| Evoke Pharma, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$24,937 in reported general payments places this provider in the 90th percentile of 225 gastroenterology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 23 | $638,762 |
| LinzessLinaclotide | 142 | $154,396 |
| EntyvioVedolizumab | 13 | $115,768 |
| RemicadeInfliximab | 12 | $96,959 |
| XifaxanRifaximin | 32 | $86,177 |
| CreonLipase/Protease/Amylase | 29 | $83,376 |
| IbsrelaTenapanor Hcl | 36 | $69,614 |
| TrulancePlecanatide | 62 | $56,116 |
| ZenpepLipase/Protease/Amylase | 14 | $41,782 |
| ViberziEluxadoline | 21 | $36,752 |
| Mesalamine | 75 | $36,276 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 413 | $25,497 |
| Dexlansoprazole DrDexlansoprazole | 59 | $16,997 |
| Alosetron Hcl | 37 | $12,920 |
| Famotidine | 622 | $12,339 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara, Remicade | $1,021 | $735,72135 claims |
| AbbVieLinzess, Creon, Viberzi | $17,870 | $274,524192 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance | $820 | $142,29394 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Entyvio | $715 | $115,76813 claims |
| Ardelyx, Inc.Ibsrela | $211 | $69,61436 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $28 | $12,27673 claims |
| Redhill Biopharma Inc.Movantik | $14 | $6,86313 claims |
| Braintree Laboratories, Inc.Sutab, Suflave | $98 | $3,78826 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 225 gastroenterology providers in Alabama.
Other gastroenterology in Mobile
- Jack DipalmaMobile$903K
- Phillip HendersonMobile$462K
- William SonnierMobile$178K
- Jorge HerreraMobile$167K
- Matthew EvesMobile$46K
- Susan FleetMobile$15K
- Jonathan SiegelMobile$15K
- Panayiotis GrevenitisMobile$11K
- Cody BarnettMobile$10K
- Mason AdamsMobile$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.